Skip to main content
. 2022 Jul 7;17(8):1874–1888. doi: 10.1016/j.stemcr.2022.06.003

Table 1.

Patient-derived fibrolamellar hepatocellular carcinoma organoids

Patient # ID -Sex Normal/primary/metastasis Previous treatment
FLC6 M1 F M-ant. Inf. Pericardial LN Naive
M2 M-ant. Sup. Pericardial LN Naive
FLC7 N M N-liver Naive
P P-liver Naive
M1 M-r periportal lymph node Naive
M2 M-l periportal lymph node Naive
FLC8 M F M-abdominal wall Experienced
FLC9 N M N-liver Experienced
M1 M-ascites Experienced
M2 M-omental nodule Experienced
FLC11 N M N-liver Experienced
M1 M-lymph node Experienced
FLC12 N M N-liver Experienced
M1 M-liver Experienced
M2 M-lymph node Experienced
M3 M-retroperitoneal lymph node Experienced
FLC13 N F N-liver Experienced
P P-liver Experienced
FLC14 N M N-liver Experienced
P P-liver Experienced
FLC15 M1 F M-lung nodule Experienced

Twenty-one patient-derived organoid lines cultured from nine patients with fibrolamellar hepatocellular carcinoma including six non-tumor liver (“normal” or N) organoid lines, three primary liver tumor (P) organoid lines, and 12 metastatic (M, M1–3) organoid lines. Patient sex, tumor location, and treatment prior to tumor resection are listed. Experienced, at least one chemotherapeutic agent; naïve, no treatment prior to resection.